The stock price performance for the year has been a mixed bag, indicating either a pessimistic or optimistic outlook depending on how you look at it. Year to date metric has recorded a gain of 9.84%.However, over the last six months, we can see a weaker performance of 19.64%. Over the last 30 days, the price of PACB has leaped by -14.10%. And in the last five days, it has surged by 1.01%.
The stock market performance of Pacific Biosciences of California Inc has been fairly unsteady. Over the last year, the company’s stock hit its highest at $7.85 on 01/26/24, while the lowest price during the same time frame was $1.16, recorded on 07/02/24.
52-week price history of PACB Stock
The history of a stock’s 52-week high and low prices can provide important information about its current state and future potential. Pacific Biosciences of California Inc’s current trading price is -74.39% away from its 52-week high, while its distance from the 52-week low is 73.28%. The stock’s price range for this period has been between $1.16 and $7.85. The Healthcare sector company’s shares saw a trading volume of about 7.51 million for the day, which was lower than the average daily volume of 9.88 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
Pacific Biosciences of California Inc (PACB) has experienced a quarterly rise of 29.68% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 550.46M and boasts a workforce of 796 employees.
How Moving Averages and Trading Volume Data Work Together
Based on Barchart.com data, the company’s moving average over the 100-day period was 1.86, with a change in price of +0.41. Similarly, Pacific Biosciences of California Inc recorded 9,084,993 in trading volume during the last 100 days, posting a change of +25.62%.
PACB’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for PACB stands at 2.03. Similarly, the long-term debt-to-equity ratio is also 2.01.
PACB Stock Stochastic Average
As of today, the raw stochastic average of Pacific Biosciences of California Inc over the past 50 days is 42.28%. This is a decrease compared to the raw stochastic average of the last 20 days, which was recorded at 49.12%. Additionally, the Stochastic %K and %D values for the company were 52.24% and 50.38%, respectively, over the past 20 days.
